Related Experiment Videos
Does smoking reduce infliximab's effectiveness against Crohn's disease?
Neeraj Narula1, Richard N Fedorak
1Division of Gastroenterology, Zeidler Ledcor Centre, University of Alberta, Edmonton, Canada.
Summary
Smoking does not significantly impact infliximab treatment effectiveness for Crohn's disease (CD). Current evidence suggests that a patient's smoking status should not influence decisions regarding infliximab therapy for CD.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Crohn's disease (CD) is a chronic inflammatory bowel disease with no cure.
- Infliximab is a biologic agent used to manage CD symptoms, but its high cost necessitates predictive response markers.
- Tobacco smoking is a known risk factor for CD development and progression.
Purpose of the Study:
- To review the existing literature on the impact of tobacco smoking on the efficacy of infliximab in treating Crohn's disease.
- To determine if smoking status is a significant predictor of infliximab response in CD patients.
Main Methods:
- Literature review of studies investigating the relationship between smoking and infliximab efficacy in Crohn's disease.
- Analysis of current research findings regarding smoking's influence on treatment outcomes.
Main Results:
- Previous studies suggested a negative impact of smoking on infliximab response in CD.
- The current body of literature does not consistently identify a significant relationship between smoking status and infliximab efficacy.
- Smoking is generally detrimental to CD course and overall health.
Conclusions:
- Current evidence does not support excluding patients from infliximab therapy based on smoking status.
- Smoking status should not be a determining factor in infliximab treatment decisions for Crohn's disease.
- Further research may be needed to clarify any subtle effects of smoking on infliximab therapy in CD.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
377
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
377
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
383
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
383
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
350
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
350
01:29Inflammatory Bowel Disease IV: Pharmacological Management
375
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
375
01:29Drugs for Treatment of Ulcerative Colitis in IBD
371
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
371
01:30Inflammatory Bowel Disease II: Crohn's Disease
825
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
825